DETECTION OF MUTATIONS RELATED TO HEREDITARY CANCER IN RELATIVES OF BREAST CANCER PATIENTS
https://doi.org/10.21294/1814-4861-2017-16-4-84-88
Abstract
The BRCA1 5382insC and CHEK2 1100 delC mutations were analyzed in 3850 of non-selected breast cancer patients residing in Novosibirsk region, Russia. One hundred seventy probands, BRCA1 5382insC or CHEK2 1100delC mutation carriers, were found. The study demonstrated that more than 80 % of probands informed relatives about their hereditary or familial cancer risk. Fifty-nine BRCA1 5382insC and CHEK2 1100 delC mutation carriers were found among 144 proband’s relatives. Mutation carriers or their relatives were interviewed two years after starting the project. At least 18 % of the mutation carriers reported primary tumor or recurrence of the tumor 2 years after starting the project.
About the Authors
G. A. Paul
Biolink Ltd.
Russian Federation
Russian Federation
Paul Galina A., MD, Head of laboratory, Biolink Ltd.
14, Razezdnaya Str., 630055-Novosibirsk, Russia.
N. A. Matyash
Biolink Ltd.
Russian Federation
Russian Federation
Matyash Natalia A., Head of the Medical Department, Biolink Ltd.
14, Razezdnaya Str., 630055-Novosibirsk, Russia.
E. E. Pisareva
Biolink Ltd; Institute of Molecular Biology and Biophysics.
Russian Federation
Russian Federation
Pisareva Ekaterina E., PhD, Research Fellow, Institute of Molecular Biology and Biophysics.
14, Razezdnaya Str., 630055-Novosibirsk, Russia.
M. S. Anisimenko
Biolink Ltd; Institute of Molecular Biology and Biophysics.
Russian Federation
Russian Federation
Anisimenko Maxim S., Research Fellow, Institute of Molecular Biology and Biophysics.
2/12, Tumakova Str., 630117-Novosibirsk, Russia.
A. E. Kozyakov
Institute of Molecular Biology and Biophysics; Novosibirsk regional oncological clinic.
Russian Federation
Russian Federation
Kozyakov Anton E., MD, oncologist, Novosibirsk Regional Oncological Clinic.
2, Plahotnogo Str., 630000-Novosibirsk, Russia.
S. P. Kovalenko
Biolink Ltd; Institute of Molecular Biology and Biophysics.
Russian Federation
Russian Federation
Kovalenko Sergei P., PhD, Head of the laboratory, Institute of Molecular Biology and Biophysics.
2/12, Tumakova Str., 630117-Novosibirsk, Russia.
References
1. Mavaddat N., Antoniou A.C., Easton D.F., Garcia-Closas M. Genetic susceptibility to breast cancer. Mol Oncol. 2010 Jun; 4 (3): 174–91. doi: 10.1016/j.molonc.2010.04.011.
2. Fischer C., Kuchenbäcker K., Engel C., Zachariae S., Rhiem K., Meindl A., Rahner N., Dikow N., Plendl H., Debatin I., Grimm T., Gadzicki D., Flöttmann R., Horvath J., Schröck E., Stock F., Schäfer D., Schwaab I., Kartsonaki C., Mavaddat N., Schlegelberger B., Antoniou A.C., Schmutzler R.; German Consortium for Hereditary Breast and Ovarian Cancer. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. J Med Genet. 2013 Jun; 50 (6): 360–7. doi: 10.1136/jmedgenet-2012-101415.
3. Kwon J.S., Gutierrez-Barrera A.M., Young D., Sun C.C., Daniels M.S., Lu K.H., Arun B. Expanding the criteria for BRCA mutation testing in breast cancer survivors J Clin Oncol. 2010 Sep 20; 28 (27): 4214–20. doi: 10.1200/JCO.2010.28.0719.
4. Iyevleva A.G., Suspitsin E.N., Kroeze K., Gorodnova T.V., Sokolenko A.P., Buslov K.G., Voskresenskiy D.A., Togo A.V., Kovalenko S.P., Stoep Nv., Devilee P., Imyanitov E.N. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett. 2010 Dec 8; 298 (2): 258–63. doi: 10.1016/j.canlet.2010.07.013.
5. Anisimenko M.S., Mitrofanov D.V., Chasovnikova O.B., Voevoda M.I., Kovalenko S.P. BRCA1 gene mutations frequency estimation by allelespecific real-time PCR of pooled genomic DNA samples. Breast. 2013 Aug; 22 (4): 532–6. doi: 10.1016/j.breast.2012.12.007.
6. Yang Y., Zhang F., Wang Y., Liu S.C. CHEK2 1100delC variant and breast cancer risk in Caucasians: a meta-analysis based on 25 studies with 29,154 cases and 37,064 controls. Asian Pac J Cancer Prev. 2012 Jul; 13 (7): 3501–5. doi: 10.7314/APJCP.2012.13.7.3501.
7. Chasovnikova O.B., Mitrofanov D.V., Anisimenko M.S., Kovalenko S.P., Lyakhovich V.V., Voevoda M.I. Prevalence of mutations BRCA1 5382insC, and CHEK2 1100delC in the population of Siberian region. Genetics. 2012; 48 (6): 768–72. [in Russian]
8. Rowland E., Plumridge G., Considine A.M., Metcalfe A. Preparing young people for future decision-making about cancer risk in families affected or at risk from hereditary breast cancer: A qualitative interview study. Eur J Oncol Nurs. 2016 Dec; 25: 9–15. doi: 10.1016/j.ejon.2016.08.006.
9. Schneider K.I., Schmidtke J. Patient compliance based on genetic medicine: a literature review. J Community Genet. 2014 Jan; 5 (1): 31–48. doi: 10.1007/s12687-013-0160-2.
10. Yagudina R.I, Kulikov A.Yu., Nguyen T., Musina N.Z. Pharmacoeconomic analysis of treatment patients with breast cancer according Russian standard. Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 2 (4): 25–33. [in Russian]
Review
For citations:
Paul G.A., Matyash N.A., Pisareva E.E., Anisimenko M.S., Kozyakov A.E., Kovalenko S.P. DETECTION OF MUTATIONS RELATED TO HEREDITARY CANCER IN RELATIVES OF BREAST CANCER PATIENTS. Siberian journal of oncology. 2017;16(4):84-88. (In Russ.) https://doi.org/10.21294/1814-4861-2017-16-4-84-88
Views:
1004
Email this article 
